{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-003606","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2026-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.003574+00:00","generated_at":"2026-05-16T08:20:22.365790+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncotelic Therapeutics grants CEO up to 26,512 Series A preferred shares based on capital structure milestones","bullets":["CEO Dr. Vuong Trieu receives 4,426 preferred shares (convertible to 4.426M common) for first milestone: converting $2.175M 2023 PPM Notes into 2025 Units.","Remaining 22,086 preferred shares vest upon three milestones: $350K debt from Mast Hill Fund with $45M market cap, conversion of $3.3M Autotelic loans, and repayment of $2.175M notes.","Each preferred share converts into 1,000 common shares; total potential dilution up to 26.512M common shares (approx. 4.99% of outstanding).","Agreement includes accelerated vesting upon termination without cause or change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-003606","json":"https://secwatch.observer/filing/0001493152-26-003606.json","markdown":"https://secwatch.observer/filing/0001493152-26-003606.md","text":"https://secwatch.observer/filing/0001493152-26-003606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315226003606/0001493152-26-003606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315226003606/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T08:20:22.365790+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}